Skip to main content
Top
Published in: BMC Health Services Research 1/2016

Open Access 01-12-2016 | Research article

Long-term costs of colorectal cancer treatment in Spain

Authors: Julieta Corral, Xavier Castells, Eduard Molins, Pietro Chiarello, Josep Maria Borras, Francesc Cots

Published in: BMC Health Services Research | Issue 1/2016

Login to get access

Abstract

Background

Assessing the long-term cost of colorectal cancer (CRC) increases our understanding of the disease burden. The aim of this paper is to estimate the long-term costs of CRC care by stage at diagnosis and phase of care in the Spanish National Health Service.

Methods

Retrospective study on resource use and direct medical cost of a cohort of 699 patients diagnosed and treated for CRC in 2000–2006, with follow-up until 30 June 2011, at Hospital del Mar (Barcelona). The Kaplan-Meier sample average estimator was used to calculate observed 11-year costs, which were then extrapolated to 16 years. Bootstrap percentile confidence intervals were calculated for the mean long-term cost per patient by stage. Phase-specific, long-term costs for the entire CRC cohort were also estimated.

Results

With regard to stage at diagnosis, the mean long-term cost per patient ranged from €20,708 (in situ) to €47,681 (stage III). The estimated costs increased at more advanced stages up to stage III and then substantially decreased in stage IV. In terms of treatment phase, the mean cost of the initial period represented 24.8 % of the total mean long-term cost, whereas the cost of continuing and advanced care phases represented 16.9 and 58.3 %, respectively.

Conclusions

This study is the first to provide long-term cost estimates for CRC treatment, by stage at diagnosis and phase of care, based on data from clinical practice in Spain, and it will contribute useful information for future studies on cost-effectiveness and budget impact of different therapeutic innovations in Spain.
Literature
1.
go back to reference Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JW, Comber H, et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer. 2013;49:1374–403.CrossRefPubMed Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JW, Comber H, et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer. 2013;49:1374–403.CrossRefPubMed
2.
go back to reference Van Cutsem E, Borràs JM, Castells A, Ciardiello F, Ducreux M, Haq A, et al. Improving outcomes in colorectal cancer: where do we go from here? Eur J Cancer. 2013;49:2476–85.CrossRefPubMed Van Cutsem E, Borràs JM, Castells A, Ciardiello F, Ducreux M, Haq A, et al. Improving outcomes in colorectal cancer: where do we go from here? Eur J Cancer. 2013;49:2476–85.CrossRefPubMed
3.
go back to reference Tol J, Punt CJ. Monoclonal antibodies in the treatment of metastatic colorectal cancer: a review. Clin Ther. 2010;32:437–53.CrossRefPubMed Tol J, Punt CJ. Monoclonal antibodies in the treatment of metastatic colorectal cancer: a review. Clin Ther. 2010;32:437–53.CrossRefPubMed
4.
go back to reference Howard DH, Kauh J, Lipscomb J. The value of new chemotherapeutic agents for metastatic colorectal cancer. Arch Intern Med. 2010;170:537–42.CrossRefPubMed Howard DH, Kauh J, Lipscomb J. The value of new chemotherapeutic agents for metastatic colorectal cancer. Arch Intern Med. 2010;170:537–42.CrossRefPubMed
5.
go back to reference Lange A, Prenzler A, Frank M, Kirstein M, Vogel A, von der Schulenburg J. A systematic review of cost-effectiveness of monoclonal antibodies for metastatic colorectal cancer. Eur J Cancer. 2014;50:40–9.CrossRefPubMed Lange A, Prenzler A, Frank M, Kirstein M, Vogel A, von der Schulenburg J. A systematic review of cost-effectiveness of monoclonal antibodies for metastatic colorectal cancer. Eur J Cancer. 2014;50:40–9.CrossRefPubMed
6.
go back to reference Jansman FG, Postma MJ, Brouwers JR. Cost considerations in the treatment of colorectal cancer. Pharmacoeconomics. 2007;25:537–62.CrossRefPubMed Jansman FG, Postma MJ, Brouwers JR. Cost considerations in the treatment of colorectal cancer. Pharmacoeconomics. 2007;25:537–62.CrossRefPubMed
7.
go back to reference Yabroff KR, Warren JL, Brown ML. Costs of cancer care in the USA: a descriptive review. Nat Clin Pract Oncol. 2007;4:643–56.CrossRefPubMed Yabroff KR, Warren JL, Brown ML. Costs of cancer care in the USA: a descriptive review. Nat Clin Pract Oncol. 2007;4:643–56.CrossRefPubMed
8.
go back to reference Ó Céilleachair AJ, Hanly P, Skally M, O’Neill C, Fitzpatrick P, Kapur K, et al. Cost comparisons and methodological heterogeneity in cost-of-illness studies: the example of colorectal cancer. Med Care. 2013;51:339–50.CrossRefPubMed Ó Céilleachair AJ, Hanly P, Skally M, O’Neill C, Fitzpatrick P, Kapur K, et al. Cost comparisons and methodological heterogeneity in cost-of-illness studies: the example of colorectal cancer. Med Care. 2013;51:339–50.CrossRefPubMed
9.
go back to reference Yabroff KR, Borowski L, Lipscomb J. Economic studies in colorectal cancer: challenges in measuring and comparing costs. J Natl Cancer Inst - Monogr. 2013;46:62–78.CrossRef Yabroff KR, Borowski L, Lipscomb J. Economic studies in colorectal cancer: challenges in measuring and comparing costs. J Natl Cancer Inst - Monogr. 2013;46:62–78.CrossRef
10.
go back to reference Corral MJ, Clopès A, Navarro M, Germà JR, Borràs JM. Impact on budget of new drugs for colorectal cancer treatment. Med Clin (Barc). 2007;129:134–6.CrossRef Corral MJ, Clopès A, Navarro M, Germà JR, Borràs JM. Impact on budget of new drugs for colorectal cancer treatment. Med Clin (Barc). 2007;129:134–6.CrossRef
11.
go back to reference Casado MA, Benavides M, Cajaraville G, Carreras MJ, Tabernero JM. Análisis coste-efectividad y de impacto presupuestario del tratamiento de primera línea del cáncer colorrectal metastásico en España. Revista Española de Economía de la Salud. 2007;6:106–18. Casado MA, Benavides M, Cajaraville G, Carreras MJ, Tabernero JM. Análisis coste-efectividad y de impacto presupuestario del tratamiento de primera línea del cáncer colorrectal metastásico en España. Revista Española de Economía de la Salud. 2007;6:106–18.
12.
go back to reference Cots F, Novoa A, Macià F, Gallén M, Mateu X, Riu M, et al. Cost hospitalari del tractament del càncer colorrectal. In: Estudis d’Economia de la Salut. Barcelona: Direcció General de Planificació i Avaluació. Departament de Salut; 2006. p. 63–89. Cots F, Novoa A, Macià F, Gallén M, Mateu X, Riu M, et al. Cost hospitalari del tractament del càncer colorrectal. In: Estudis d’Economia de la Salut. Barcelona: Direcció General de Planificació i Avaluació. Departament de Salut; 2006. p. 63–89.
13.
go back to reference Sobin LH, Wittekind CH. TNM Classification of Malignant Tumors - Sixth Edition. Volume 5th. New York: Wiley-Liss; 2002. Sobin LH, Wittekind CH. TNM Classification of Malignant Tumors - Sixth Edition. Volume 5th. New York: Wiley-Liss; 2002.
14.
go back to reference Gold MI, Siegel L, Weinstein RM. Cost-Effectiveness in Health and Medicine. Oxford: Oxford University Press; 1996. Gold MI, Siegel L, Weinstein RM. Cost-Effectiveness in Health and Medicine. Oxford: Oxford University Press; 1996.
15.
go back to reference Raikou M, McGuire A. Estimating medical care costs under conditions of censoring. J Health Econ. 2004;23:443–70.CrossRefPubMed Raikou M, McGuire A. Estimating medical care costs under conditions of censoring. J Health Econ. 2004;23:443–70.CrossRefPubMed
16.
go back to reference Young TA. Estimating mean total costs in the presence of censoring: a comparative assessment of methods. Pharmacoeconomics. 2005;23:1229–42.CrossRefPubMed Young TA. Estimating mean total costs in the presence of censoring: a comparative assessment of methods. Pharmacoeconomics. 2005;23:1229–42.CrossRefPubMed
17.
go back to reference Fenn P, McGuire A, Phillips V, Backhouse M, Jones D. The analysis of censored treatment cost data in economic evaluation. Med Care. 1995;33:851–63.CrossRefPubMed Fenn P, McGuire A, Phillips V, Backhouse M, Jones D. The analysis of censored treatment cost data in economic evaluation. Med Care. 1995;33:851–63.CrossRefPubMed
18.
go back to reference Etzioni R, Riley GF, Ramsey SD, Brown M. Measuring costs - Administrative claims data, clinical trials, and beyond. Med Care. 2002;40(6 Supl):63–72. Etzioni R, Riley GF, Ramsey SD, Brown M. Measuring costs - Administrative claims data, clinical trials, and beyond. Med Care. 2002;40(6 Supl):63–72.
19.
go back to reference Hallstrom AP, Sullivan SD. On estimating costs for economic evaluation in failure time studies. Med Care. 1998;36:433–6.CrossRefPubMed Hallstrom AP, Sullivan SD. On estimating costs for economic evaluation in failure time studies. Med Care. 1998;36:433–6.CrossRefPubMed
20.
go back to reference Etzioni RD, Feuer E, Sullivan SD, Lin DY, Hu CC, Ramsey SD. On the use of survival analysis techniques to estimate medical care costs. J Health Econ. 1999;18:365–80.CrossRefPubMed Etzioni RD, Feuer E, Sullivan SD, Lin DY, Hu CC, Ramsey SD. On the use of survival analysis techniques to estimate medical care costs. J Health Econ. 1999;18:365–80.CrossRefPubMed
21.
go back to reference O’Hagan A, Stevens JW. On estimators of medical costs with censored data. J Health Econ. 2004;23:615–25.CrossRefPubMed O’Hagan A, Stevens JW. On estimators of medical costs with censored data. J Health Econ. 2004;23:615–25.CrossRefPubMed
22.
go back to reference Etzioni R, Ramsey SD, Berry K, Brown M. The impact of including future medical care costs when estimating the costs attributable to a disease: a colorectal cancer case study. Health Econ. 2001;10:245–56.CrossRefPubMed Etzioni R, Ramsey SD, Berry K, Brown M. The impact of including future medical care costs when estimating the costs attributable to a disease: a colorectal cancer case study. Health Econ. 2001;10:245–56.CrossRefPubMed
23.
go back to reference Brown ML, Riley GF, Potosky AL, Etzioni RD. Obtaining long-term disease specific costs of care - Application to Medicare enrollees diagnosed with colorectal cancer. Med Care. 1999;37:1249–59.CrossRefPubMed Brown ML, Riley GF, Potosky AL, Etzioni RD. Obtaining long-term disease specific costs of care - Application to Medicare enrollees diagnosed with colorectal cancer. Med Care. 1999;37:1249–59.CrossRefPubMed
24.
go back to reference Maroun J, Ng E, Berthelot JM, Le Petit C, Dahrouge S, Flanagan WM, et al. Lifetime costs of colon and rectal cancer management in Canada. Chronic Dis Can. 2002;24:91–8. Maroun J, Ng E, Berthelot JM, Le Petit C, Dahrouge S, Flanagan WM, et al. Lifetime costs of colon and rectal cancer management in Canada. Chronic Dis Can. 2002;24:91–8.
25.
go back to reference Ramsey SD, Berry K, Etzioni R. Lifetime cancer-attributable cost of care for long term survivors of colorectal cancer. Am J Gastroenterol. 2002;97:440–5.CrossRefPubMed Ramsey SD, Berry K, Etzioni R. Lifetime cancer-attributable cost of care for long term survivors of colorectal cancer. Am J Gastroenterol. 2002;97:440–5.CrossRefPubMed
26.
go back to reference Ramsey SD, Mandelson MT, Berry K, Etzioni R, Harrison R. Cancer-attributable costs of diagnosis and care for persons with screen-detected versus symptom-detected colorectal cancer. Gastroenterology. 2003;125:1645–50.CrossRefPubMed Ramsey SD, Mandelson MT, Berry K, Etzioni R, Harrison R. Cancer-attributable costs of diagnosis and care for persons with screen-detected versus symptom-detected colorectal cancer. Gastroenterology. 2003;125:1645–50.CrossRefPubMed
27.
go back to reference Chang S, Long SR, Kutikova L, Bowman L, Finley D, Crown WH, et al. Estimating the cost of cancer: Results on the basis of claims data analyses for cancer patients diagnosed with seven types of cancer during 1999 to 2000. J Clin Oncol. 2004;22:3524–30.CrossRefPubMed Chang S, Long SR, Kutikova L, Bowman L, Finley D, Crown WH, et al. Estimating the cost of cancer: Results on the basis of claims data analyses for cancer patients diagnosed with seven types of cancer during 1999 to 2000. J Clin Oncol. 2004;22:3524–30.CrossRefPubMed
28.
go back to reference Kerrigan M, Howlader N, Mandelson MT, Harrison R, Mansley EC, Ramsey SD. Costs and survival of patients with colorectal cancer in a health maintenance organization and a preferred provider organization. Med Care. 2005;43:1043–8.CrossRefPubMed Kerrigan M, Howlader N, Mandelson MT, Harrison R, Mansley EC, Ramsey SD. Costs and survival of patients with colorectal cancer in a health maintenance organization and a preferred provider organization. Med Care. 2005;43:1043–8.CrossRefPubMed
29.
go back to reference Paramore LC, Thomas SK, Knopf KB, Cragin LS, Fraeman KH. Estimating costs of care for patients with newly diagnosed metastatic colorectal cancer. Clin Colorectal Cancer. 2006;6:52–8.CrossRefPubMed Paramore LC, Thomas SK, Knopf KB, Cragin LS, Fraeman KH. Estimating costs of care for patients with newly diagnosed metastatic colorectal cancer. Clin Colorectal Cancer. 2006;6:52–8.CrossRefPubMed
30.
go back to reference Lang K, Lines LM, Lee DW, Korn JR, Earle CC, Menzin J. Lifetime and treatment-phase costs associated with colorectal cancer: evidence from SEER-Medicare data. Clin Gastroenterol Hepatol. 2009;7:198–204.CrossRefPubMed Lang K, Lines LM, Lee DW, Korn JR, Earle CC, Menzin J. Lifetime and treatment-phase costs associated with colorectal cancer: evidence from SEER-Medicare data. Clin Gastroenterol Hepatol. 2009;7:198–204.CrossRefPubMed
31.
go back to reference Luo Z, Bradley CJ, Dahman BA, Gardiner JC. Colon cancer treatment costs for Medicare and dually eligible beneficiaries. Health Care Financ Rev. 2010;31:35–50.PubMed Luo Z, Bradley CJ, Dahman BA, Gardiner JC. Colon cancer treatment costs for Medicare and dually eligible beneficiaries. Health Care Financ Rev. 2010;31:35–50.PubMed
32.
go back to reference Brown ML, Riley GF, Schussler N, Etzioni R. Estimating health care costs related to cancer treatment from SEER-Medicare data. Med Care. 2002;40(8 Suppl):104–17. Brown ML, Riley GF, Schussler N, Etzioni R. Estimating health care costs related to cancer treatment from SEER-Medicare data. Med Care. 2002;40(8 Suppl):104–17.
33.
go back to reference Riley GF, Potosky AL, Lubitz JD, Kessler LG. Medicare payments from diagnosis to death for elderly cancer patient by stage at diagnosis. Med Care. 1995;3:828–41.CrossRef Riley GF, Potosky AL, Lubitz JD, Kessler LG. Medicare payments from diagnosis to death for elderly cancer patient by stage at diagnosis. Med Care. 1995;3:828–41.CrossRef
Metadata
Title
Long-term costs of colorectal cancer treatment in Spain
Authors
Julieta Corral
Xavier Castells
Eduard Molins
Pietro Chiarello
Josep Maria Borras
Francesc Cots
Publication date
01-12-2016
Publisher
BioMed Central
Published in
BMC Health Services Research / Issue 1/2016
Electronic ISSN: 1472-6963
DOI
https://doi.org/10.1186/s12913-016-1297-6

Other articles of this Issue 1/2016

BMC Health Services Research 1/2016 Go to the issue